BioNTech signed a Letter of Intent with the State of Victoria in Australia on a strategic partnership between the State and BioNTech to collaborate on the analysis and growth of potential mRNA-based vaccines and therapies. As a part of the partnership, the events will set up a analysis and innovation heart in Melbourne to facilitate the transition of encouraging tutorial analysis into scientific growth.
BioNTech plans to arrange a scientific scale end-to-end mRNA manufacturing facility based mostly on its BioNTainer resolution in Melbourne with the goal of supporting the design, manufacture, and scientific testing of product candidates.
“Science and innovation can solely make a distinction whether it is utilized exterior of the laboratories and reaches individuals worldwide. This partnership is a serious step ahead to allow entry to mRNA know-how and promote collaborations within the Asia-Pacific area,” mentioned Ugur Sahin, MD, CEO, and co-founder of BioNTech. “Australia offers wonderful tutorial analysis, and we’re trying ahead to collaborating with world-class scientists and researchers to strengthen Australia’s mRNA ecosystem and to collectively develop potential novel remedies and vaccines for individuals worldwide.”
Analysis and innovation heart
As a part of this collaboration, the State of Victoria and BioNTech will set up a analysis and innovation heart, directed in partnership with the State, with the goal to help Australia’s mRNA ecosystem by curating tasks and to find out their potential transition into preclinical and scientific growth, supported by BioNTech’s recommendation and know-how.
The partnership can even embody the analysis and growth of experimental therapies, together with mRNA-based product candidates for indications with excessive unmet medical want, for example in oncology. BioNTech will help the R&D efforts on a project-by-project foundation.
BioNTech, which can even help native supply by growing and commissioning an end-to-end clinical-scale manufacturing facility for mRNA-based medicines and product candidates in Melbourne, has developed the BioNTainer, a cellular modular manufacturing unit requiring restricted house for operation, permitting for native manufacturing of various mRNA-based constructs and merchandise throughout quite a lot of indications.
BioNTech intends to additional strengthen the scientific growth capabilities in Australia and contains websites that goal to speed up the event of its scientific stage oncology pipeline which presently encompasses a complete of 18 product candidates in 23 ongoing scientific trials. BioNTech is presently recruiting most cancers sufferers for 2 Section 2 mRNA-based product candidates in Australia–BNT111 and BNT113–and plans to additional broaden its scientific growth, together with for the corporate’s candidate BNT211, which mixes a CAR-T cell remedy method with an mRNA vaccine.